1. Introduction {#sec1}
===============

Obesity, a chronic metabolic disorder, is strongly associated with morbidity and mortality as well as a reduced life expectancy \[[@B1]\]. Obesity is defined as an excessive accumulation of adipose tissue. Globally, 1.9 billion adults are overweight or obese, and this figure has more than doubled in the past two decades \[[@B2]\]. Epidemiological studies show that overweight and obese status in adults significantly increases the risks of numerous cardiovascular and circulatory disorders, for example, hypertension, stroke, coronary artery disease, and heart failure \[[@B1], [@B3]\]. Some of the complex, interrelated pathological states, for example, altered lipid profile and elevated blood pressure, also associated with obesity, subsequently induce insulin resistance, vascular oxidative stress, vascular endothelial dysfunction, and other debilitations \[[@B4]--[@B6]\].

The vascular endothelium, which is a single layer of cells lining the interior surface of blood vessels, plays a key role in vasomotor regulation mainly through the nitric oxide- (NO-) dependent signaling pathways \[[@B7]\]. The vascular endothelium is a sensitive structure which is susceptible to damage by certain lipids and inflammatory mediators \[[@B8]\]. Adipose tissue is well known to be associated with inflammatory processes, and it is also implicated in the production of reactive oxygen species (ROS) \[[@B9]\]. Multiple studies provide evidence that vascular endothelial function (EF) is impaired in the setting of obesity \[[@B6], [@B10], [@B11]\]. Endothelial dysfunction is considered to be an early precursor and common pathological feature of vascular diseases \[[@B12]\].

Endothelial dysfunction is commonly evaluated by flow-mediated dilatation (FMD) in human studies. The FMD is a noninvasive clinical tool that measures shear stress-mediated vasodilatory response and depends on NO bioavailability \[[@B7], [@B13]\]. One meta-analysis has reported an association between a 1% decrease in FMD and an 8% increase in the risk of future cardiovascular events \[[@B14]\]. While pharmacological intervention is often used to improve EF or body weight (e.g., topiramate and metformin), regular exercise training is a promising nonpharmacological option in obesity treatment \[[@B15]\].

Although a recent meta-analysis demonstrated the beneficial effect of exercise training on FMD in both obese and nonobese adults \[[@B16]\], the included studies pool data from both obese and nonobese groups, thus raising the question of whether obesity status is a confounding factor in accurate evaluation of FMD. Furthermore, the optimal intensity, modality, and duration of exercise for improving FMD are controversial \[[@B17]--[@B20]\]. These and similar studies also suggest there are several other potential factors confounding measurement of FMD in the setting of obesity.

To address the inconclusive findings, we conducted a meta-analysis to quantitatively evaluate the relationship between exercise training and EF in overweight and obese adults. We compared the effects of different characteristics of exercise interventions and participants\' demographics on FMD.

2. Methods {#sec2}
==========

2.1. Literature Search {#sec2.1}
----------------------

Source of data was identified by keyword searched from four electronic databases: the PubMed/Medline, Scopus, and CINAHL. The keywords used to identify the relevant studies were "obesity", "overweight", "exercise", "training", "flow mediated dilatation", "flow mediated dilation", and "FMD". Additional potential sources were identified by hand search using personal databases and a reference list of published studies.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The studies were included in the review if sufficient information was reported that allowed us to compute the standardized mean difference of FMD. Specific inclusion criteria for eligible studies were the study (1) included the value of relative FMD; (2) included exercise intervention at least 7 days; (3) considered only overweight and/or obese adults; and (4) is written in English language and published in peer-reviewed journals through June 2016. Furthermore, studies were excluded if they were purposefully designed for examining the effects of weight loss medication, antiandrogens, fertility treatments, glucocorticoids, or oral contraceptives.

2.3. Coding and Data Extraction {#sec2.3}
-------------------------------

The two authors (YS, SJ) independently coded the identified studies using extraction sheets. The characteristics of the studies were coded for descriptive purposes and moderator analyses. Based on the procedures recommended by Lipsey and Wilson (2005), the outcome and moderator variables were extracted. The effect size (ES) of outcome variable, FMD, was computed using (a) before and after mean difference from intervention groups divided by pooled standard deviation (SD) and (b) mean difference between intervention and control groups divided by pooled SD. Also, moderator variables which may affect overall ES of FMD were coded as follows: body weight change, diet intervention, exercise duration/type/intensity, comorbidity, and baseline Body Mass Index (BMI). Exercise intensity and type were classified as low, moderate, and high intensity using the definition of the American College of Sports Medicine \[[@B21]\].

All coded data were crosschecked with authors for establishing consistency, and discrepancies were resolved by discussion. [Figure 1](#fig1){ref-type="fig"} illustrates the schematic flow diagram of this study describing the inclusion and exclusion procedures for study selection \[[@B22]\].

2.4. Study Quality Rating {#sec2.4}
-------------------------

The methodological quality of selected studies was assessed using the Physiotherapy Evidence Database (PEDro) scale \[[@B23], [@B24]\]. This scale consists of 11 items: random allocation, concealed allocation, similarity at baseline, subject blinding, therapist blinding, assessor blinding, \>85% follow-up for at least one key outcome, intention-to-treat analysis, between-group statistical comparison for at least one key outcome, and point and variability measures for at least one key outcome. The quality of studies is determined based on the average of overall scores (range = 0--10; each item, except for item 1, contributes one point) where higher scores indicate better methodological quality. The average total PEDro score is 5.0 ± 1.6 (mean ± SD) based on 27,444 records from the PEDro database on January 2017. The scoring ≥ 6/10 was considered "moderate to high" for methodological quality \[[@B25]\].

2.5. Data Analysis {#sec2.5}
------------------

All analyses were run in Comprehensive Meta-Analysis version-3 software with a significance level of 0.05. Because we assumed that the variety of research designs with study characteristics might affect the true ES from one study to another, a random effects model was used to estimate the overall ES and 95% confidence intervals (CIs). The measure of ES used for the present study is the standardized mean difference, Cohen\'s*d*. The ESs were evaluated based on Cohen\'s guideline, small (0.2), medium (0.5), and large (0.8) \[[@B26]\]. The Cochran\'s*Q* homogeneity statistic was used to determine the heterogeneity of the mean ESs across the groups. Moderator analyses were conducted to test the ES difference among the categorical subgroups of each moderator. The mean ES and 95 CI of each subgroup was also examined to see if an exercise intervention has an effect greater than zero. In addition, we examined the funnel plots, the Duval and Tweedie\'s trim and fill method, and Egger\'s test to detect the publication bias as all studies were published in the peer-reviewed journals in which the results are possibly subjected to publication bias.

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

[Figure 1](#fig1){ref-type="fig"} outlines the flow diagram of the study selection process. The literature search identified 91 articles. We next reviewed the articles in full text to determine final eligibility. 17 studies ultimately met the eligibility criteria providing sufficient information for computing ESs. Some of the studies included results from separate, independent trials testing the effects of two or more exercise modalities on EF, so the 17 studies yielded a total of 34 ESs for the final meta-analysis.

3.2. Publication Bias {#sec3.2}
---------------------

The funnel plot examination showed that the publication bias had little influence on our result. The studies included in the present meta-analysis were symmetrically distributed around the mean ES. The Duval and Tweedie\'s trim and fill method also predicted no missing study to this meta-analysis. However, the regression intercept (3.37) from Egger\'s test results was statistically significant (*p* = 0.001) that a potential publication bias for this meta-analysis should be noted for its interpretation.

3.3. Study Characteristics {#sec3.3}
--------------------------

The characteristics of these studies are shown in [Table 1](#tab1){ref-type="table"}. Studies from around the world were included, including North America, Australia, South America, Europe, and Asia. They included women and men (mean age = 47.23) who are overweight or obesity with or without comorbidity. One trial used only men, 17 trials used only females, and 16 trials used both sexes. The included studies that accounted for other potential confounders such as smoking. 16 of 34 trials in 17 studies were RCTs with no exercise intervention control group. [Table 2](#tab2){ref-type="table"} shows the characteristics of interventions within the included studies. 71% of trials (*n* = 24 trials) incorporated aerobic exercise; 18% (*n* = 6 trials) and 11% (*n* = 4 trials) of trials incorporated resistance exercise and combined with aerobic and resistance exercise, respectively. [Table 3](#tab3){ref-type="table"} shows FMD protocol and outcomes. 23 trials in 17 studies reported fasting time (ranged from 0.5 hours to overnight fasting). Brachial artery FMD was measured in all of the included studies. 71% studies reported mean and SD of FMD percentage at preintervention and postintervention, and the rest of the studies reported amount of change or 95% confidence interval (CI). The mean and SD of FMD was 7.15% ± 3.05 (range 2.7 to 11.28%) before intervention and 8.67% ± 2.62 (range 4 to 12.9%) after intervention, and rate of change for FMD was 1.17% ± 1.63 (range −1.3 to 5%) in the treatment group. In the control group, the mean and SD of FMD was 5.69% ± 2.12 (range 2.5 to 9.9%) before intervention and 6.65% ± 2.46 (range 3.8 to 10.1%) after intervention, and rate of change for FMD was 0.61% ± 2.16 (range −0.7 to 4.9%).

3.4. Quality of Included Studies {#sec3.4}
--------------------------------

Quality score by the PEDro scale was 7.2 ± 1.5 (ranged from 5 to 9), the median score of 8 of a maximum possible of 10 ([Table 4](#tab4){ref-type="table"}). This score is equivalent to moderate to high quality \[[@B25]\]. All of the studies satisfied the following criteria: baseline comparability, intention-to-treat analysis, and mean and variability data. No study reported having blinded therapists.

3.5. Overall Effect Size {#sec3.5}
------------------------

The overall mean ES was 0.522 (95% CI = 0.257, 0.786) and statistically significant. This quantitative synthesis yielded a medium and positive ES using a random effect model. This indicates that exercise training is effective in improving FMD in overweight and obese adults. There was observed to be heterogeneous (*Q*~*b*~ = 239, *p* ≤ 0.001, *I*^2^ = 86.19), suggesting that moderator analyses are needed to better understand the exercise intervention effect on FMD. [Figure 2](#fig2){ref-type="fig"} provides Forest plot with ESs of the analysis results.

3.6. Moderator Analysis {#sec3.6}
-----------------------

The moderator analyses were performed to examine the effect of body weight change, diet intervention, exercise modality, comorbidity, and baseline BMI. The results demonstrated that only comorbidity status explained the heterogeneity of ESs (*Q*~*b*~ = 6.39, df = 1, and *p* = 0.011). [Table 5](#tab5){ref-type="table"} shows the results of moderator analyses, which includes ESs, CIs, and Cochran\'s *Q* statistics for each moderator variables. A large ES was found in the combination exercise, low intensity exercise, and comorbidity subgroups (ES = 0.82\~1.24). A moderate to large ES was found in body weight loss, with and without diet intervention, more than 12-week exercise duration, aerobic exercise, and between 30 and 34.9 baseline BMI (ES = 0.51\~0.71).

4. Discussion {#sec4}
=============

In this meta-analysis, we found 34 trials from 17 studies including 1,045 overweight and obese adults. The meta-analysis result showed that exercise training significantly improves vascular function as measured by FMD of the brachial artery. The studies were randomized controlled trials of control and noncontrol groups of Asian and Western adult populations. Endothelial dysfunction is inherent in overweight and obese adults, and exercise training is universally accepted to ameliorate the obesity-associated endothelial dysfunction in healthy adults \[[@B16], [@B27]\]; however, more examination of the specific effects of exercise training on EF in overweight and obese population is still needed. Therefore, we combined data from each of the clinical trials to understand the relationship between exercise training and EF in overweight and obese adults.

Our results demonstrated that exercise has a moderate benefit on the improvement of FMD on overweight and obese adult populations in exercise intervention studies. When we probed moderators to examine the possible associations with ESs, we found that only comorbidity status influences the effectiveness of exercise intervention on EF. To our knowledge, we are the first to report this result. The finding could explain why exercise may not reverse the reduction of FMD attributable solely to obesity in isolation, whereas exercise may reverse the portion attributable to a comorbidity. While the explanation contrasts two previous meta-analyses \[[@B16], [@B28]\] showing that exercise is an effective method to improve FMD, they use pooled data from both obese and nonobese groups. If obesity acts on FMD in an exercise-independent way, it is possible that our finding of an FMD improvement results from the influence of exercise intervention on the portion of FMD decrement attributable to the comorbidity, rather than on the portion of FMD decrement attributable to obesity. We were unable to extrapolate the underlying mechanism of this finding, because it is beyond the scope of our study. Further research is required to examine different populations according to study characteristics (age, type of disease, stage of disease, exercise intensity, exercise type, treatment modality, etc.).

The examination of mean ES and 95 CI of each subgroup showed that ES is above medium in the subgroups with weight loss whereas there is no significant benefit of exercise intervention in the weight gain group. Although the mechanism of the effects of weight loss on FMD in overweight and obese adults requires more elucidation, numerous studies confirm the positive effects of weight loss by exercise on FMD. The beneficial effect of weight reduction by lifestyle changes, such as exercise to improve vascular function in obese adults, is strongly supported in \[[@B29]\], and a meta-analysis of the relationship between weight change and EF has reported a positive correlation between weight loss and an increase in FMD \[[@B28]\]. Therefore, it is speculated that weight reduction may be a major factor enhancing FMD in obese individuals and may depend on the method of weight reduction.

A study of the effect of surgically induced weight loss on FMD in hypertensive obese patients showed that bariatric surgery-induced weight loss improves blood pressure (BP), high-sensitivity C-reactive protein (hs-CRP), leptin, homeostasis model assessment (HOMA-IR), and abdominal fat, whereas FMD does not improve \[[@B30]\]. A study examining the effects of dietary weight loss on vascular function in obese men demonstrated that diet-induced weight reduction decreases aortic stiffness, total and low-density lipoprotein cholesterol, triglycerides, insulin resistance, and BP without alteration of FMD \[[@B31]\]. Similarly, our results demonstrate the significant benefit of exercise on FMD in overweight and obese adults regardless of diet control. Taken together, the above results indicating that exercise-mediated weight loss may improve FMD, but not diet control or surgery, suggest that exercise is a key regulator of FMD in overweight and obese adults. The notion that exercise-induced shear stress improves FMD in overweight and obese adults through an increase in the activity and expression of endothelial nitric oxide synthase (eNOS) that augments NO bioavailability also supports the suggestion \[[@B32]--[@B34]\].

We also found a moderate to large beneficial effect of exercise in the longer-period intervention subgroup than with 12 weeks of exercise program, and no significant benefit in the group with less than 12 weeks of intervention. We suggest that at least 12 weeks of exercise intervention may improve FMD in overweight and obese adults. Although previous reviews hypothesized that a longer duration may increase efficacy and maintain the effect on EF from the exercise intervention \[[@B16], [@B27]\], our meta-analysis provides the first quantitative evidence of the optimal exercise intervention duration to improve EF in overweight and obese adults.

As mentioned, exercise modality and intensity to improve EF remains controversial. For example, a meta-analysis of obese and nonobese adults showed that any type of exercise, including resistance, aerobic, and combined training improves EF \[[@B16]\]; however, another meta-analysis demonstrated that resistance exercise associates with increased arterial stiffness \[[@B18]\]. Our results confirmed no effect in the resistance exercise, medium to large effect in the aerobic exercise, and large effect in the combined exercise. We interpret our findings with caution, because more than 70% of included studies utilized aerobic exercises as an intervention modality. Furthermore, a recent study showed that high intensity exercise improves FMD more than moderate intensity, because higher intensity exercise causes greater shear stress resulting in more NO activation \[[@B17]\], even though other studies reported that high intensity exercise significantly reduces FMD \[[@B19], [@B20]\]. Our meta-analysis results showed that high intensity exercise has no effect, whereas low and moderate intensity exercise have large and medium ESs, respectively. Again, we interpret the results with caution, because a limited number of studies reported results for high (*n* = 1) and low (*n* = 3).

Moderator analysis also demonstrated that adults with a BMI 30--34.9 (level 1 obesity) have large and medium to large beneficial effect from exercise, respectively, whereas adults without a comorbidity and BMI \< 30 or ≥35 have no significant benefit from exercise. Previously, Joris et al. \[[@B28]\] reported that the effects on FMD linearly relate to amount of weight loss in groups with obesity-related morbidities compared with healthy adults. Since this study pooled obese and nonobese adults and it did not break down groups by method of weight loss, a direct comparison with our study is not possible, because our data include only obese adults \[[@B28]\].

The effect of exercise on FMD may also depend on baseline BMI. Our result showed that only adults with level 1 obesity have a benefit from exercise training on FMD. A meta-analysis by Ashor et al., however, showed a greater effect of exercise on FMD in nonobese individuals than in obese individuals \[[@B16]\]. Again, a direct comparison is not possible. Further research should clarify the relationship between baseline obesity and exercise effect on FMD.

This study must be interpreted in the context of multiple limitations. First, the range in FMD levels in the studies is relatively small, and there is substantially less data for those with BMI \> 35. Second, there were methodological limitations. FMD is well known for being operator and protocol dependent, and there was considerable variation in FMD data collection methodology \[[@B35], [@B36]\]. Therefore, further well-controlled studies are needed to draw accurate conclusions.

In summary, our meta-analysis indicates that exercise training is able to improve EF in overweight and obese adults, and that the effect of exercise may depend on the different characteristics of exercise intervention and on participants\' demographics.
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###### 

Baseline characteristics of the included studies.

  Author and year                       County           Subject characteristics of treatment group   Subject characteristics of control group   Smoker                                                                                               
  ------------------------------------- ---------------- -------------------------------------------- ------------------------------------------ -------- ---------------------------------- ---- ---- ---- -------- ---- ----------------- ---- ---- --------------
  Ades et al. (2011) a \[[@B37]\]       USA              23                                           Both                                       66       Coronary heart disease             32   −8                                                  Not included
  Ades et al. (2011) b \[[@B37]\]       USA              15                                           Both                                       62       Coronary heart disease             33   −2                                                  Not included
  Baynard et al. (2009) a \[[@B38]\]    USA              10                                           Both                                       52       Metabolic syndrome                 34   0                                                   Not included
  Baynard et al. (2009) b \[[@B38]\]    USA              10                                           Both                                       52       Metabolic syndrome                 34   0                                                   Not included
  Baynard et al. (2009) c \[[@B38]\]    USA              11                                           Both                                       53       Healthy                            33   0                                                   Not included
  Baynard et al. (2009) d \[[@B38]\]    USA              11                                           Both                                       53       Healthy                            33   0                                                   Not included
  Bhutani et al. (2013) a \[[@B39]\]    USA              18                                           Both                                       45       Healthy                            35   −6   25   Both     42   Healthy           35   −3   Not included
  Bhutani et al. (2013) b \[[@B39]\]    USA              24                                           Both                                       42       Healthy                            35   −1   16   Both     49   Healthy           35   0    Not included
  Blumenthal et al. (2010) \[[@B40]\]   USA              49                                           Both                                       52       HTN                                34   −9   46   Both     52   HTN               33   0    Included
  Choo et al. (2014) a \[[@B41]\]       South of Korea   39                                           Female                                     42       Healthy                            29   −2                                                  Included
  Choo et al. (2014) b \[[@B41]\]       South of Korea   39                                           Female                                     42       Healthy                            29   −2                                                  Included
  Choo et al. (2014) c \[[@B41]\]       South of Korea   39                                           Female                                     42       Healthy                            29   −2                                                  Included
  Choo et al. (2014) d \[[@B41]\]       South of Korea   26                                           Female                                     46       Healthy                            28   −2                                                  Included
  Choo et al. (2014) e \[[@B41]\]       South of Korea   26                                           Female                                     46       Healthy                            28   −2                                                  Included
  Choo et al. (2014) f \[[@B41]\]       South of Korea   26                                           Female                                     46       Healthy                            28   −1                                                  Included
  Choo et al. (2014) g \[[@B41]\]       South of Korea   27                                           Female                                     42       Healthy                            29   −1                                                  Included
  Choo et al. (2014) h \[[@B41]\]       South of Korea   27                                           Female                                     42       Healthy                            29   −1                                                  Included
  Choo et al. (2014) i \[[@B41]\]       South of Korea   27                                           Female                                     42       Healthy                            29   −1                                                  Included
  Cotie et al. (2014) \[[@B42]\]        Canada           20                                           Female                                     30       Healthy                            32   −6                                                  NR
  Davison et al. (2008) a \[[@B43]\]    Australia        13                                           Both                                       45       Healthy                            34   1    11   Both     44   Healthy           35   2     
  Davison et al. (2008) b \[[@B43]\]    Australia        13                                           Both                                       46       Healthy                            33   1    12   Both     45   Healthy           33   −2    
  Fayh et al. (2013) \[[@B44]\]         Brazil           17                                           Both                                       31       Healthy                            35   −4   18   Both     32   Healthy           35   −5   Not included
  Franklin et al. (2015) \[[@B45]\]     USA              10                                           Female                                     30       Healthy                            34   −1   8    Female   31   Healthy           32   0    Not included
  Hamdy et al. (2003) \[[@B46]\]        USA              24                                           Both                                       49       Insulin resistance syndrome        37   −7                                                  Not included
  Kwon et al. (2011) a \[[@B47]\]       South of Korea   13                                           Female                                     56       Type 2 diabetes                    27   −2   15   Female   59   Type 2 Diabetes   27   −1   NR
  Kwon et al. (2011) b \[[@B47]\]       South of Korea   12                                           Female                                     56       Type 2 diabetes                    27   −1   15   Female   59   Type 2 Diabetes   27   −1   NR
  Olson et al. (2006) \[[@B48]\]        USA              15                                           Female                                     38       Healthy                            28   2    15   Female   38   Healthy           28   0    Not included
  Pugh et al. (2014) \[[@B49]\]         UK               13                                           Both                                       50       Nonalcoholic fatty liver disease   30   −2   8    Both     47   Healthy           30   −1    
  Robinson et al. (2016) \[[@B50]\]     USA              10                                           Both                                       34       Healthy                            32   −3   9    Both     28                     33   0    Not included
  Swift et al. (2012) a \[[@B51]\]      USA              68                                           Female                                     57       Elevated BP                        32   −1   23   Female   57   Elevated BP       32   −1    
  Swift et al. (2012) b \[[@B51]\]      USA              32                                           Female                                     56       Elevated BP                        33   −1   23   Female   57   Elevated BP       32   −1    
  Swift et al. (2012) c \[[@B51]\]      USA              32                                           Female                                     56       Elevated BP                        31   −1   23   Female   57   Elevated BP       32   −1    
  Vinet et al. (2011) \[[@B52]\]        France           10                                           Male                                       51       Healthy                            33   −2                                                  Not included
  Wycherley et al. (2008) \[[@B53]\]    Australia        13                                           Both                                       52       Type 2 diabetes                    34   −8   16   Both     53   Type 2 Diabetes   35   −9    

*Note*. NR: no report.

###### 

Characteristics of intervention of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and year                       Exercise intervention   Additional diet intervention                                                                               
  ------------------------------------- ----------------------- ------------------------------ ------------ -------------------- ----------------------------------------- -----
  Ades et al. (2011) a \[[@B37]\]       Aerobic                 16                             1--3         40--60               Low (high-caloric-expenditure)            Yes

  Ades et al. (2011) b \[[@B37]\]       Aerobic                 16                             1--3         25--40               Higher (lower-caloric-expenditure)        Yes

  Baynard et al. (2009) a \[[@B38]\]    Aerobic                 10 days                        6            60                   70--75% of VO~2~ peak                     No

  Baynard et al. (2009) b \[[@B38]\]    Aerobic                 10 days                        6            60                   70--75% of VO~2~ peak                     No

  Baynard et al. (2009) c \[[@B38]\]    Aerobic                 10 days                        6            60                   70--75% of VO~2~ peak                     No

  Baynard et al. (2009) d \[[@B38]\]    Aerobic                 10 days                        6            60                   70--75% of VO~2~ peak                     No

  Bhutani et al. (2013) a \[[@B39]\]    Aerobic                 12                             3            24--40               60--75% of HRmax                          Yes

  Bhutani et al. (2013) b \[[@B39]\]    Aerobic                 12                             3            24--40               60--75% of HRmax                          No

  Blumenthal et al. (2010) \[[@B40]\]   Aerobic                 16                             3            45                   70--85% of HRR                            Yes

  Choo et al. (2014) a \[[@B41]\]       Aerobic                 12                             3            60                   50--70% of HRR                            Yes

  Choo et al. (2014) b \[[@B41]\]       Aerobic                 24                             3            60                   50--70% of HRR                            Yes

  Choo et al. (2014) c \[[@B41]\]       Aerobic                 38                             3            60                   50--70% of HRR                            Yes

  Choo et al. (2014) d \[[@B41]\]       Resistance              12                             3            60                   40--60% of MS                             Yes

  Choo et al. (2014) e \[[@B41]\]       Resistance              24                             3            60                   40--60% of MS                             Yes

  Choo et al. (2014) f \[[@B41]\]       Resistance              38                             3            60                   40--60% of MS                             Yes

  Choo et al. (2014) g \[[@B41]\]       Combined                12                             3            60 (30 + 30)         50--70% of HRR\                           Yes
                                                                                                                                 40--60% of MS                             

  Choo et al. (2014) h \[[@B41]\]       Combined                24                             3            60 (30 + 30)         50--70% of HRR\                           Yes
                                                                                                                                 40--60% of MS                             

  Choo et al. (2014) i \[[@B41]\]       Combined                38                             3            60 (30 + 30)         50--70% of HRR\                           Yes
                                                                                                                                 40--60% of MS                             

  Cotie et al. (2014) \[[@B42]\]        Combined                16                             7            Expend 250 kal/day   70%/3 set 10 rep                          Yes

  Davison et al. (2008) a \[[@B43]\]    Aerobic                 12                             At least 1   45                   75% of HRmax                              Yes

  Davison et al. (2008) b \[[@B43]\]    Aerobic                 12                             At least 1   45                   75% of HRmax                              Yes

  Fayh et al. (2013) \[[@B44]\]         Aerobic                 10                             3            45                   70% of HRmax                              Yes

  Franklin et al. (2015) \[[@B45]\]     Circuit-based RT        8                              2                                 80--90% of 10 RM                          No

  Hamdy et al. (2003) \[[@B46]\]        Aerobic                 24                             3            30                   60--80% of HRmax                          Yes

  Kwon et al. (2011) a \[[@B47]\]       Aerobic                 12                             5            60                   Moderate (3.6--6 METs)                    No

  Kwon et al. (2011) b \[[@B47]\]       Resistance              12                             5            60                   Bands provide 1.2--3.2 kg of resistance   No

  Olson et al. (2006) \[[@B48]\]        Resistance              1 year                         At least 2                        3 sets 8--10 repetitions                  No

  Pugh et al. (2014) \[[@B49]\]         Aerobic                 12                             5            45                   60% of HRR                                Yes

  Robinson et al. (2016) \[[@B50]\]     Aerobic                 8                              3            30--45               75% of HRmax                              No

  Swift et al. (2012) a \[[@B51]\]      Aerobic                 24                             3-4          Expend 4 kcal/kg     50% of VO~2~ peak                         No

  Swift et al. (2012) b \[[@B51]\]      Aerobic                 24                             3-4          Expend 8 kcal/kg     50% of VO~2~ peak                         No

  Swift et al. (2012) c \[[@B51]\]      Aerobic                 24                             3-4          Expend 12 kcal/kg    50% of VO~2~ peak                         No

  Vinet et al. (2011) \[[@B52]\]        Aerobic                 8                              3            45                   LIPOXmaxHR ± 5                            No

  Wycherley et al. (2008) \[[@B53]\]    Aerobic                 12                             4-5          50--60               60--80% of HRmax                          Yes
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. HRR: Heart Rate Reserve, MS: Maximum Strength, LIPOXmaxHR: maximum lipid-oxidation point.

###### 

FMD protocol and outcomes.

  Author anB3:H25                       Timing of measurement   Placed cuff       Treatment group   Control group                                                        
  ------------------------------------- ----------------------- ----------------- ----------------- --------------- ---------- ----------------- ------ ------ --------- ------------------
  Ades et al. (2011) a \[[@B37]\]       Fast                    Brachial artery   2.9               3.6             6.5        3.5                                        
  Ades et al. (2011) b \[[@B37]\]       Fast                    Brachial artery   3.6               4.1             4.9        3.8                                        
  Baynard et al. (2009) a \[[@B38]\]    Overnight fast          Brachial artery   8                 1.5             7.5        1.2                                        
  Baynard et al. (2009) b \[[@B38]\]    0.5--1 h ingestion      Brachial artery   6                 1.1             6.3        1.1                                        
  Baynard et al. (2009) c \[[@B38]\]    Overnight fast          Brachial artery   10.4              1.1             10.2       0.9                                        
  Baynard et al. (2009) d \[[@B38]\]    0.5--1 h ingestion      Brachial artery   9.8               0.8             8.5        0.8                                        
  Bhutani et al. (2013) a \[[@B39]\]    NR                      Brachial artery   3.8               1.2             6.4        0.8               4.8    1.2    9.7       1.8
  Bhutani et al. (2013) b \[[@B39]\]    NR                      Brachial artery   6.8               1.3             7.2        1.4               7      3.3    6.3       3
  Blumenthal et al. (2010) \[[@B40]\]   Overnight fast          Brachial artery                                     4^z^       1                               3.8^z^    1
  Choo et al. (2014) a \[[@B41]\]       Overnight fast          Brachial artery   11.28             3.5             11.55      3.8                                        
  Choo et al. (2014) b \[[@B41]\]       Overnight fast          Brachial artery   11.28             3.5             11.08      4.05                                       
  Choo et al. (2014) c \[[@B41]\]       Overnight fast          Brachial artery   11.28             3.5             10.7       3.75                                       
  Choo et al. (2014) d \[[@B41]\]       Overnight fast          Brachial artery   10.32             3.8             11.22      4.43                                       
  Choo et al. (2014) e \[[@B41]\]       Overnight fast          Brachial artery   10.32             3.8             10.89      4.33                                       
  Choo et al. (2014) f \[[@B41]\]       Overnight fast          Brachial artery   10.32             3.8             11.54      4.99                                       
  Choo et al. (2014) g \[[@B41]\]       Overnight fast          Brachial artery   11.02             3.49            11.1       3.4                                        
  Choo et al. (2014) h \[[@B41]\]       Overnight fast          Brachial artery   11.02             3.49            12.41      4.27                                       
  Choo et al. (2014) i \[[@B41]\]       Overnight fast          Brachial artery   11.02             3.49            11.3       4.04                                       
  Cotie et al. (2014) \[[@B42]\]        NR                      Brachial artery   4                 0.5             6.9        0.6                                        
  Davison et al. (2008) a \[[@B43]\]    NR                      Brachial artery   5.37              0.68            −0.4^a^    0.77^b^           3.65   1.4    −0.3^a^   0.53^b^
  Davison et al. (2008) b \[[@B43]\]    NR                      Brachial artery   4.05              0.51            1.5^a^     0.68^b^           4.12   0.75   1.8^a^    0.89^b^
  Fayh et al. (2013) \[[@B44]\]         Overnight fast          Brachial artery   8.1               3.6             10.7       3.6               9.9    3.4    10.1      5.8
  Franklin et al. (2015) \[[@B45]\]     NR                      Brachial artery   9.5               1.6             9.8        1.6               8.4    3.5    8         3.3
  Hamdy et al. (2003) \[[@B46]\]        NR                      Brachial artery   7.9               1               12.9       1.2                                        
  Kwon et al. (2011) a \[[@B47]\]       10 h fast               Brachial artery   4.3               1.6             6.4        1.9               4.7    1.9    4         1.9
  Kwon et al. (2011) b \[[@B47]\]       10 h fast               Brachial artery   4.9               2.5             5.6        2.8               4.7    1.9    4         1.9
  Olson et al. (2006) \[[@B48]\]        Overnight fast          Brachial artery   6.3               0.2             6.2        0.1               6.3    0.2    6         0.1
  Pugh et al. (2014) \[[@B49]\]         NR                      Brachial artery   4.79                              8.57       (2.24--4.71)^c^   5.94          5.32      (−1.72--1.46)^c^
  3.47^a^                               −0.13^a^                                                                                                                         
  Robinson et al. (2016) \[[@B50]\]     NR                      Brachial artery   8.6               4.8             7.7        2.79              9.3    4.2    9.3       4.1
  Swift et al. (2012) a \[[@B51]\]      Fast                    Brachial artery   4                 2.6             1^a^       (0.29--1.76)^c^   4.7    2.4    −0.5^a^   (−1.79--0.74)^c^
  Swift et al. (2012) b \[[@B51]\]      Fast                    Brachial artery   4.4               2.4             1.5^a^     (0.48--2.62)^c^   4.7    2.4    −0.5^a^   (−1.79--0.74)^c^
  Swift et al. (2012) c \[[@B51]\]      Fast                    Brachial artery   3.7               2.6             1.2^a^     (0.1--2.24)^c^    4.7    2.4    −0.5^a^   (−1.79--0.74)^c^
  Vinet et al. (2011) \[[@B52]\]        Overnight fast          Brachial artery   2.7               0.4             4.8        0.5                                        
  Wycherley et al. (2008) \[[@B53]\]    Fast                    Brachial artery   4.2               1.2             −0.52^a^   1.06^b^           2.5    0.9    0.03^a^   0.26^b^

*Note*. ^a^Δmean; ^b^ΔSD; ^c^95% confidence interval; ^z^adjusted for value of preintervention; NR: no report.

###### 

Methodological scores by Physiotherapy Evidence Database (PEDro) scale.

  Studies                               PEDro criterion   Total score                                            
  ------------------------------------- ----------------- ------------- ---- ---- --- --- --- --- ---- ---- ---- ---
  Ades et al. (2011) \[[@B37]\]         1                 1             1    1    1   0   0   1   1    1    1    9
  Baynard et al. (2009) \[[@B38]\]      1                 0             0    1    0   0   0   1   1    1    1    6
  Bhutani et al. (2013) \[[@B39]\]      1                 1             1    1    0   0   0   0   1    1    1    7
  Blumenthal et al. (2010) \[[@B40]\]   1                 1             1    1    0   0   0   1   1    1    1    8
  Choo et al. (2014) \[[@B41]\]         1                 1             1    1    1   0   1   0   1    1    1    9
  Cotie et al. (2014) \[[@B42]\]        0                 0             0    1    0   0   0   1   1    1    1    5
  Davison et al. (2008) \[[@B43]\]      1                 1             1    1    1   0   1   0   1    1    1    9
  Fayh et al. (2013) \[[@B44]\]         1                 1             1    1    0   0   0   0   1    1    1    7
  Franklin et al. (2015) \[[@B45]\]     1                 1             1    1    0   0   0   1   1    1    1    8
  Hamdy et al. (2003) \[[@B46]\]        1                 0             0    1    0   0   0   0   1    1    1    5
  Kwon et al. (2011) \[[@B47]\]         1                 1             1    1    0   0   0   1   1    1    1    8
  Olson et al. (2006) \[[@B48]\]        1                 1             1    1    0   0   1   1   1    1    1    9
  Pugh et al. (2014) \[[@B49]\]         1                 1             1    1    0   0   0   0   1    1    1    7
  Robinson et al. (2016) \[[@B50]\]     1                 0             0    1    0   0   0   0   1    1    1    5
  Swift et al. (2012) \[[@B51]\]        1                 1             1    1    0   0   1   0   1    1    1    8
  Vinet et al. (2011) \[[@B52]\]        1                 0             0    1    0   0   0   1   1    0    1    5
  Wycherley et al. (2008) \[[@B53]\]    1                 1             1    1    0   0   0   1   1    1    1    8
                                                                                                                 
  *Total*                               16                12            12   17   3   0   4   9   17   16   17    

*Note*. Each number of PEDro criterion is represented as follows: 1: inclusion and source; 2: random allocation; 3: concealed allocation; 4: baseline comparability; 5: blinded subjects; 6: blinded therapists; 7: blinded assessors; 8: outcomes for \>85%; 9: intention-to-treat analysis; 10: between-group comparisons; 11: mean and variability data.

###### 

Subgroup analysis.

  Moderator variable   *n*   ES     95% CI   *Q* ~*b*~   
  -------------------- ----- ------ -------- ----------- ------------
  Body weight change                                      
   Increase            7     0.10   −0.50    0.70        2.545
   0--2.9 kg loss      19    0.61   0.26     0.97        
   ≥3 kg loss          8     0.70   0.12     1.28        
  Diet intervention                                       
   Yes                 20    0.51   0.18     0.85        0.008
   No                  14    0.54   0.11     0.97        
  Exercise duration                                       
   \<12 weeks          8     0.09   −0.50    0.68        2.868
   12--23 weeks        15    0.61   0.20     1.02        
   ≥24 weeks           11    0.71   0.24     1.18        
  Exercise type                                           
   Resistance          6     0.43   −0.22    1.07        0.601
   Aerobic             24    0.52   0.18     0.85        
   Combined            4     0.82   0.01     1.62        
  Exercise intensity                                      
   Low                 3     1.24   0.29     2.19        2.401
   Moderate            30    0.47   0.19     0.75        
   High                1     0.27   −1.38    1.93        
  Comorbidity                                             
   No                  21    0.26   −0.06    0.58        6.392^*∗*^
   Yes                 13    0.95   0.52     1.37        
  Baseline BMI                                            
   25--29.9            12    0.31   −0.11    0.73        1.647
   30--34.9            19    0.67   0.30     1.04        
   ≥35                 3     0.66   −0.28    1.61        

*Note*. ^*∗*^*p* \< 0.05.

[^1]: Academic Editor: Raffaele Serra
